<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145687</url>
  </required_header>
  <id_info>
    <org_study_id>Met LN</org_study_id>
    <nct_id>NCT04145687</nct_id>
  </id_info>
  <brief_title>Metformin In Prevention of Lupus Nephritis</brief_title>
  <official_title>Metformin In Prevention Of Lupus Nephritis In High Risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lupus nephritis (LN) is a main manifestation of systemic lupus erythematosus (SLE), which
      will largely effect the prognosis of SLE patients. Our previous 10-year data showed that the
      development of LN is most common in the first year of SLE, occupying about 17%. And our group
      has established a prediction model to predict the 1-year probability of LN for SLE patients
      without renal involvement. Our previous proof-of-concept trial and multicenter, randomized,
      double-blind, placebo-controlled trial indicated that metformin seemed to have potential to
      reduce the new-onset of LN in SLE patients (Unpublished data, in review). So the
      investigators tried to illustrate whether metformin has effect to prevent the development of
      lupus nephritis in high risk SLE patients based on LN prediction model.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of new-onset LN</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients with new-onset lupus nephritis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of SLEDAI score</measure>
    <time_frame>12 months</time_frame>
    <description>Change of SLEDAI score during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Prednisone</measure>
    <time_frame>12 months</time_frame>
    <description>Change of Prednisone during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of LN</measure>
    <time_frame>12 months</time_frame>
    <description>Time to new-onset of lupus nephritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of proteinuria</measure>
    <time_frame>12 months</time_frame>
    <description>Change of 24-hour proteinuria during follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500mg tid</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New-onset of SLE (within 1 year)

          -  Meet the 1997 ACR criteria of SLE

          -  1-year risk of developing LN higher than 50% based on LN prediction model.

          -  All the patients received standard care of therapy.
             (mycophenolate/azathioprine/cyclosporin/tacrolimus/methotrexate/leflunomide were
             allowed).

          -  Sign the informed consent.

        Exclusion Criteria:

          -  Patients with kidney involvement at screening were excluded

          -  Patients with severe SLE were excluded, such as neuropsychiatric and cardiac
             involvement

          -  Cyclophosphamide or biologics were not allowed.

          -  Alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) &gt; 2 times upper
             normal limits; creatinine clearance rate &lt; 60ml/min;

          -  Previous exposure of metformin within 30 days before screening; or previous history of
             intolerant to metformin;

          -  Patients who diagnosed of diabetes mellitus;

          -  Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fangfang Sun, MD</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fangfang Sun, MD</last_name>
      <phone>+8615800901145</phone>
      <email>Fiona_rj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ting Li, MD</last_name>
      <phone>+8613916927066</phone>
      <email>leeting007@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Ting Li</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

